Literature DB >> 29309998

Drugs which influence serotonin transporter and serotonergic receptors: Pharmacological and clinical properties in the treatment of depression.

Przemysław Paweł Taciak1, Natalia Lysenko2, Aleksander Paweł Mazurek3.   

Abstract

Depression is nowadays a major contributor to global burden of disease. The most commonly prescribed drugs influence monoaminergic pathways, mainly concentrating on serotonin. Unfortunately, there are several drawbacks associated with these drugs, namely late onset of action, risk of suicide and adverse effects: mainly nausea, vomiting and sexual dysfunction. Therefore there is still need for new drugs with possibly high efficacy and fewer side effects. In this paper selected compounds which inhibit serotonin reuptake by acting on the serotonin transporter (SERT) and various serotoninergic receptors are presented. We also discuss the ways in which their mechanism of action can be modified to improve pharmacological profile. Here, we focus on describing drugs' potency, efficacy and adverse effects. Additional applications, apart from depression, are also discussed.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Antidepressants; Major depressive disorder; Monoamine reuptake inhibitors; Serotonergic receptors; Serotonin transporter

Mesh:

Substances:

Year:  2017        PMID: 29309998     DOI: 10.1016/j.pharep.2017.07.011

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  8 in total

1.  Interleukin-6 Induced by Social Stress Promotes a Unique Transcriptional Signature in the Monocytes That Facilitate Anxiety.

Authors:  Anzela Niraula; Kristina G Witcher; John F Sheridan; Jonathan P Godbout
Journal:  Biol Psychiatry       Date:  2018-10-10       Impact factor: 13.382

2.  Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.

Authors:  Alexei Verkhratsky; Vladimir Parpura; Caterina Scuderi; Baoman Li
Journal:  Adv Neurobiol       Date:  2021

3.  Peripheral microvascular serotoninergic signaling is dysregulated in young adults with major depressive disorder.

Authors:  Jody L Greaney; Gabrielle A Dillon; Erika F H Saunders; Lacy M Alexander
Journal:  J Appl Physiol (1985)       Date:  2019-11-21

4.  Effect of serotonin modulation on dystrophin-deficient zebrafish.

Authors:  Janelle M Spinazzola; Matthias R Lambert; Devin E Gibbs; James R Conner; Georgia L Krikorian; Prithu Pareek; Carlo Rago; Louis M Kunkel
Journal:  Biol Open       Date:  2020-08-28       Impact factor: 2.422

5.  MAOI Antidepressants: Could They Be a Next-Generation ICB Therapy?

Authors:  James Brown; Bo Li; Lili Yang
Journal:  Front Immunol       Date:  2022-03-14       Impact factor: 7.561

Review 6.  A simple mechanistic terminology of psychoactive drugs: a proposal.

Authors:  Roland Seifert; Bastian Schirmer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-13       Impact factor: 3.000

7.  Establishment and evaluation of a novel mouse model of peri/postmenopausal depression.

Authors:  Ling Zhang; Lu-Lu Cao; Dan-Dan Yang; Jian-Hua Ding; Xu-Dong Guo; Teng-Fei Xue; Xiao-Jie Zhao; Xiu-Lan Sun
Journal:  Heliyon       Date:  2019-02-04

8.  A Meta-Analysis of 5-Hydroxytryptamine Receptor 1B Polymorphisms With Risk of Major Depressive Disorder and Suicidal Behavior.

Authors:  Pingliang Yang; Mengchang Yang; Peng Li; Dejun Cao; Daoyin Gong; Jiahua Lv; Linmei Pu; Sizhou Huang; Yundan Liang
Journal:  Front Psychiatry       Date:  2021-07-12       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.